BioMarin Pharmaceutical Inc. (0HNC.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
87.08+5.24 (+6.40%)
As of 4:46PM GMT. Market open.
| Previous close | 81.84 |
| Open | 87.36 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 87.08 - 87.37 |
| 52-week range | 87.08 - 87.37 |
| Volume | 600 |
| Avg. volume | N/A |
| Market cap | 15.859B |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | 19.10 |
| EPS (TTM) | 4.56 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
BIOMARIN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN).
- Zacks
Stock Market News for Jan 12, 2021
Benchmarks declined from record highs on Monday as investors weighed impact of rise in coronavirus cases and ongoing political turmoil on economic growth.
- Zacks
BioMarin (BMRN) Reveals 1-Year Data on Hemophilia Gene Therapy
BioMarin (BMRN) announces one-year update from GENEr8-1 phase III study, which shows that valoctocogene roxaparvovec significantly reduces annualized bleeding rate (ABR) by 84% in patients with hemophilia A.
© 2021 Verizon Media. All rights reserved.
